We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
ACC.24 - Daniel Gaudet shares the results of the SHASTA-2 trial. The APOC3 RNAi plozasiran is highly effective and well tolerated in patients with severe hypertriglyceridemia, and demonstrated sustainability in the efficacy through week 48, according to Daniel Gaudet.
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Daniel Gaudet, MD, PhD is a clinician-researcher in lipidology and professor of medicine at the Université de Montreal (U de M), in Montreal, QC, Canada.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 9 april 2024
ACC.24 - Daniel Gaudet shares the results of the SHASTA-2 trial. The APOC3 RNAi plozasiran is highly effective and well tolerated in patients with severe hypertriglyceridemia, and demonstrated sustainability in the efficacy through week 48, according to Daniel Gaudet.
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Daniel Gaudet, MD, PhD is a clinician-researcher in lipidology and professor of medicine at the Université de Montreal (U de M), in Montreal, QC, Canada.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 9 april 2024
Stay current with the best on medical education
